Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant ...

Nath figured the drug might have a similar effect in people with long COVID, based in part on the PML results. Last June, Nath approached Merck to ask for supplies of Keytruda to test that hypothesis.

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

An international clinical trial has identified a medication that can help prevent symptomatic COVID-19 in people exposed within households.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially ...